Last reviewed · How we verify
Dose D1 of interleukin-2
Dose D1 of interleukin-2 is a Cytokine Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development for Melanoma, Renal cell carcinoma.
Interleukin-2 stimulates T-cell proliferation and activation.
Interleukin-2 stimulates T-cell proliferation and activation. Used for Melanoma, Renal cell carcinoma.
At a glance
| Generic name | Dose D1 of interleukin-2 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Cytokine |
| Target | Interleukin-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Interleukin-2 is a cytokine that plays a crucial role in the immune response, particularly in the activation and proliferation of T-cells. It is used to treat various types of cancer, including melanoma and renal cell carcinoma.
Approved indications
- Melanoma
- Renal cell carcinoma
Common side effects
- Flu-like symptoms
- Fatigue
- Nausea
Key clinical trials
- Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (PHASE1)
- A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma (PHASE1)
- PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. (PHASE2)
- Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata (PHASE1, PHASE2)
- Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) (PHASE2)
- Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes (PHASE2)
- MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin (PHASE1, PHASE2)
- Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose D1 of interleukin-2 CI brief — competitive landscape report
- Dose D1 of interleukin-2 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Dose D1 of interleukin-2
What is Dose D1 of interleukin-2?
How does Dose D1 of interleukin-2 work?
What is Dose D1 of interleukin-2 used for?
Who makes Dose D1 of interleukin-2?
What drug class is Dose D1 of interleukin-2 in?
What development phase is Dose D1 of interleukin-2 in?
What are the side effects of Dose D1 of interleukin-2?
What does Dose D1 of interleukin-2 target?
Related
- Drug class: All Cytokine drugs
- Target: All drugs targeting Interleukin-2 receptor
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Melanoma
- Indication: Drugs for Renal cell carcinoma
- Compare: Dose D1 of interleukin-2 vs similar drugs
- Pricing: Dose D1 of interleukin-2 cost, discount & access